Overview
Fetal hemoglobin is the primary oxygen-carrying hemoglobin during fetal life and plays a vital role in transporting oxygen from the mother to the developing fetus. It has a distinct structure composed of two alpha and two gamma chains, which gives it a higher affinity for oxygen compared to adult hemoglobin.
Production of fetal hemoglobin begins early in pregnancy and remains high until birth, after which it gradually declines as adult hemoglobin synthesis increases. In healthy individuals, fetal hemoglobin levels fall to very low levels within the first year of life.
Symptoms
Fetal hemoglobin itself does not cause symptoms, but altered levels are associated with various hematological conditions. Persistently elevated fetal hemoglobin in older children or adults may modify disease presentation in disorders such as sickle cell disease and beta-thalassemia, often resulting in milder symptoms. In newborns, normal high levels of fetal hemoglobin support oxygen delivery and do not produce any adverse clinical features.
Causes
High fetal hemoglobin levels are a normal physiological finding in fetuses and newborns. Persistently raised levels beyond infancy may occur due to genetic conditions such as hereditary persistence of fetal hemoglobin, beta-thalassemia, and sickle cell disease. Bone marrow stress, aplastic anemia, leukemias, and myeloproliferative disorders can also lead to increased fetal hemoglobin production. Pregnancy and certain medications, such as hydroxyurea, stimulate gamma-globin gene expression and increase fetal hemoglobin levels. Reduced transition from fetal to adult hemoglobin synthesis may also contribute to elevated levels.
Risk Factors
Genetic mutations affecting globin gene regulation are the major risk factors for persistently elevated fetal hemoglobin. Individuals with inherited hemoglobin disorders, bone marrow disorders, or chronic hemolytic anemias are more likely to show increased levels. Use of drugs that induce fetal hemoglobin production and physiological states such as pregnancy can influence levels. Newborns naturally have high fetal hemoglobin as part of normal development.
Prevention
There is no need to prevent fetal hemoglobin production in newborns, as it is essential for fetal and early neonatal survival. In inherited hemoglobin disorders, early diagnosis and regular monitoring help in disease management. Therapeutic induction of fetal hemoglobin, such as with hydroxyurea in sickle cell disease, is beneficial and reduces disease severity. Genetic counseling and newborn screening programs aid in early detection and appropriate clinical management of hemoglobin-related disorders.
